Platelet‐to‐lymphocyte ratio and absolute monocyte count have prognostic potential in primary myelodysplastic neoplasms

Abstract

AbstractIntroductionThe platelet‐to‐lymphocyte ratio (PLR), peripheral blood absolute monocyte count (AMC), and monocyte‐to‐lymphocyte ratio (MLR) are considered biomarkers of systemic immune and inflammation response. However, their prognostic potential in patients with myelodysplastic neoplasms (MDS) remains unclear. This study aimed to explore the predictive impact of PLR, MLR, and AMC on MDS outcomes.MethodsIn total, 334 patients with primary MDS were included between January 2016 and December 2021 and were retrospectively followed up until December 31, 2022. The prognostic significance of PLR, MLR, and AMC was assessed using univariate and multivariate analyses, and predictive models were generated to estimate MDS outcomes. The area under their receiver operating curves was computed to compare the predictive power of these models.ResultsFifty‐one patients had disease progression, and 103 patients died during follow‐up. In multivariate analyses, a higher PLR was an adverse independent factor for overall survival (OS) (p = 0.011), whereas a higher AMC indicated shorter progression‐free survival (p = 0.003). The prognostic model incorporating PLR, MLR, and AMC with the Revised International Prognostic Scoring System (IPSS‐R) risk categorization showed higher performance in predicting OS than the model that only utilized the IPSS‐R category.ConclusionElevated PLR and increased AMC had independent prognostic value for adverse outcomes in patients with MDS. PLR, MLR, and AMC enhanced the IPSS‐R risk categorization for OS prediction in MDS.